Cabaletta Bio prices $87M public offering of 7.25M shares at $12.00 per share

Cabaletta Bio, Inc.

Pricing of 7,250,000 shares at $12.00 per share; gross proceeds expected $87M before expenses.
Underwriters granted 30-day option for up to an additional 1,087,500 shares.
Net proceeds estimated at $81.18M after underwriting discounts and offering expenses.
Proceeds to fund expanded clinical development of CABA-201, manufacturing, and CAART programs.
Offering expected to close May 22, 2023; TD Cowen, Evercore ISI, Guggenheim lead.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Cabaletta Bio, Inc. entered into Underwriting Agreement with Cowen and Company, LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC valued at 7,250,000 shares of common stock at $12.00 per share, option for additional 1,087,500 shares (effective 2023-05-17).

Action: entry
Agreement: underwriting
Counterparty: Cowen and Company, LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC
Value: 7,250,000 shares of common stock at $12.00 per share, option for additional 1,087,500 shares
Effective: 2023-05-17

Exact text from the filing

On May 17, 2023, Cabaletta Bio, Inc. (the “Company” or “Cabaletta”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC (collectively, the “Underwriters”), related to a public offering (the “Offering”) of 7,250,000 shares of common stock of the Company, par value $0.00001 per share (the “Common Stock”) at a price to the public of $12.00 per share.

View on SEC.gov

800 material agreements filed in the last 30 days. Browse all material agreements →

Cabaletta Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-148212

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.